Neuroinflammation in Glioblastoma: Progress and Perspectives
- PMID: 39061427
- PMCID: PMC11274945
- DOI: 10.3390/brainsci14070687
Neuroinflammation in Glioblastoma: Progress and Perspectives
Abstract
Glioblastoma is the most common and malignant primary brain tumor, with high morbidity and mortality. Despite an aggressive, multimodal treatment regimen, including surgical resection followed by chemotherapy and radiotherapy, the prognosis of glioblastoma patients remains poor. One formidable challenge to advancing glioblastoma therapy is the complexity of the tumor microenvironment. The tumor microenvironment of glioblastoma is a highly dynamic and heterogeneous system that consists of not only cancerous cells but also various resident or infiltrating inflammatory cells. These inflammatory cells not only provide a unique tumor environment for glioblastoma cells to develop and grow but also play important roles in regulating tumor aggressiveness and treatment resistance. Targeting the tumor microenvironment, especially neuroinflammation, has increasingly been recognized as a novel therapeutic approach in glioblastoma. In this review, we discuss the components of the tumor microenvironment in glioblastoma, focusing on neuroinflammation. We discuss the interactions between different tumor microenvironment components as well as their functions in regulating glioblastoma pathogenesis and progression. We will also discuss the anti-tumor microenvironment interventions that can be employed as potential therapeutic targets.
Keywords: glioblastoma; neuroinflammation; therapy; tumor microenvironment (TME).
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Front Immunol. 2020 Jul 17;11:1402. doi: 10.3389/fimmu.2020.01402. eCollection 2020. Front Immunol. 2020. PMID: 32765498 Free PMC article. Review.
-
Neuroinflammation in Glioblastoma: The Role of the Microenvironment in Tumour Progression.Curr Cancer Drug Targets. 2024;24(6):579-594. doi: 10.2174/0115680096265849231031101449. Curr Cancer Drug Targets. 2024. PMID: 38310461 Review.
-
Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma.BioDrugs. 2023 Jul;37(4):489-503. doi: 10.1007/s40259-023-00598-2. Epub 2023 May 31. BioDrugs. 2023. PMID: 37256535 Review.
-
Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy.Cancers (Basel). 2021 Aug 24;13(17):4255. doi: 10.3390/cancers13174255. Cancers (Basel). 2021. PMID: 34503065 Free PMC article. Review.
-
Macrophages and microglia: the cerberus of glioblastoma.Acta Neuropathol Commun. 2021 Mar 25;9(1):54. doi: 10.1186/s40478-021-01156-z. Acta Neuropathol Commun. 2021. PMID: 33766119 Free PMC article. Review.
Cited by
-
Towards non-invasive diagnosis of glioblastoma: identifying metabolic biomarkers in liquid biopsies using a ROC-based approach.Discov Oncol. 2025 Aug 2;16(1):1456. doi: 10.1007/s12672-025-03310-8. Discov Oncol. 2025. PMID: 40751888 Free PMC article.
-
Autoimmune Encephalitis-like Presentation of Glioblastoma: Get to Know This Rare Occurrence.J Clin Med. 2025 May 29;14(11):3807. doi: 10.3390/jcm14113807. J Clin Med. 2025. PMID: 40507568 Free PMC article.
References
-
- Wen P.Y., Weller M., Lee E.Q., Alexander B.M., Barnholtz-Sloan J.S., Barthel F.P., Batchelor T.T., Bindra R.S., Chang S.M., Chiocca E.A., et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources